- Report
- September 2023
- 120 Pages
Global
From €5665EUR$5,950USD£4,842GBP
- Report
- February 2021
- 360 Pages
United States
From €2285EUR$2,400USD£1,953GBP
- Report
- February 2019
- 105 Pages
Global
From €1228EUR$1,290USD£1,050GBP
- Report
- February 2021
- 254 Pages
Global
From €10468EUR$10,995USD£8,948GBP
- Report
- June 2019
- 15 Pages
Japan
€9521EUR$10,000USD£8,138GBP
- Report
- June 2019
- 16 Pages
Global
€9521EUR$10,000USD£8,138GBP
- Report
- March 2024
- 50 Pages
Global
From €2523EUR$2,650USD£2,157GBP
- Report
- November 2021
- 620 Pages
Global
From €3808EUR$4,000USD£3,255GBP
Elvitegravir is a drug used to treat immune disorders, such as HIV and AIDS. It is a type of integrase inhibitor, which works by blocking the action of the enzyme integrase, which is responsible for the integration of HIV DNA into the host cell. Elvitegravir is usually used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of contracting the virus.
Elvitegravir is available in both oral and injectable forms. It is generally well tolerated, with few side effects. Common side effects include nausea, headache, and diarrhea. Elvitegravir is generally considered to be a safe and effective treatment for HIV and AIDS.
The Elvitegravir market is highly competitive, with several companies offering the drug. Some of the major players in the market include Gilead Sciences, Merck, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more